Overview: Nasal ipratropium is used to help reduce symptoms of a runny nose. It works by reducing the amount of liquid and mucus made in your nose. Common side effects can include dryness of the nose, ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using Atrovent UDV? Atrovent Unit Dose Vial (UDV) contains ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using Atrovent Inhalation Solution? Atrovent Inhalation ...

Ipratropium bromide 17micrograms/inh; metered dose inhaler; CFC-free. Prime before first use and after 3 days of non-use by releasing 2 test sprays away from the face. Insert metal canister into clear ...

Lupin is releasing Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, which are the generic of Boehringer Ingelheim’s Atrovent Nasal Spray, 0.03% and 0.06%. Ipratropium Bromide Nasal ...

Review the side-effects of Ipratropium Bromide as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In ...

According to IQVIA, the U.S. sales for Atrovent ® HFA were approximately $112 million for the 12 months ended December 31, 2025. Amphastar plans to launch its Ipratropium Bromide HFA Inhalation ...

Global pharma major Lupin Limited (Lupin) announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for ...

HINES, Ill. Patients with chronic obstructive pulmonary disease who take the drug ipratropium bromide for preventing bronchospasm increased their risk of death from cardiovascular causes, according to ...

ATROVENT HFA prescription and dosage sizes information for physicians and healthcare professionals. Pharmacology, adverse reactions, warnings and side effects.

RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's ...